The deal represents an expansion of Boehringer Ingelheim’s investments in the CLD treatment space and scales Ochre Bio’s ambitions, specifically around MASH cirrhosis.
Novo snatches heart disease biotech Cardior Pharmaceuticals for $1.1B
Novo’s acquisition of Cardior gives it access to CDR132L, a treatment for heart failure currently in a Phase 2 trial, and boosts its focus on cardiovascular.
AstraZeneca expands into rare endocrinology with $1B deal for Amolyt Pharma
The Inhibrx pickup gives Sanofi access to INBRX-101, a human recombinant protein that is being investigated in patients with a rare disease known as alpha-1 antitrypsin deficiency.
How biotech companies are standing out during JPM Week
The discovery collab between Lilly and Prism, worth north of $600 million, promises to yield fresh targets that are readily druggable with small molecules.
Merck acquires preclinical biotech Caraway Therapeutics for up to $610M
Caraway Therapeutics brings three preclinical programs in Parkinson’s and rare diseases to Merck, which is putting down $610 million total for the deal.
Legend Biotech exec details $100M lung cancer treatment deal with Novartis
Legend’s subsidiary is licensing LB2102 and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 to Novartis for $100 million upfront with the potential to receive up to $1.1 billion in milestone payments.